SK biopharmaceuticals Co., Ltd.
326030
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
SK biopharmaceuticals Co., Ltd. began new drug research and development in 1993 to discover the SK Group's next-generation growth engine, and has focused on developing innovative new drugs for the central nervous system, in particular for epilepsy, targeting the vast global new drug market. The company has achieved results including the US FDA NDA approval and launch of the licensed-out sleep disorder drug solriamfetol (July 2019, product name SUNOSI(R)); the FDA NDA approval (November 2019) and US launch (May 2020, product name XCOPRI(R)) of cenobamate, its flagship epilepsy treatment; licensing-out to Europe and EC marketing authorization (March 2021) and European market launch (June 2021, product name ONTOZRY(R)); licensing-out to Japan (October 2020); licensing-out to China and Canada (December 2021); licensing-out to Israel (May 2022) and 17 countries in Latin America (July 2022); licensing-out to 16 countries in the MENA region (August 2023); and licensing-out to 30 countries including Korea (January 2024).
代表理事
Lee Donghun
成立日期
2011年4月1日
法人类型
韩国综合股价指数
行业分类
Research and experimental development on natural sciences
法人注册号
11011-4570720
营业执照号
101-86-62394
电话号码
031-8093-0114
传真号码
031-8093-0001
网站
www.skbp.com
公司地址
221 Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
产品与服务
评论